Sean Ekins, Ph.D., D.Sc., Collaborations Pharmaceuticals, Inc.

Sean Ekins, Ph.D., D.Sc. Sean graduated from the University of Aberdeen; receiving hisM.Sc., Ph.D. in Clinical Pharmacology and D.Sc. in Science. He was a postdoctoral fellow at Lilly Research Laboratories, worked as a senior scientist at Pfizer and then Eli Lilly. He went on to become Associate Director of Computational Drug Discovery at Concurrent Pharmaceuticals Inc. and Vice President of Computational Biology at GeneGo. Sean is currently co-founder and CEO at Phoenix Nest Inc. focused on Sanfilippo Syndrome and Founder and CEO of Collaborations Pharmaceuticals, Inc. which uses machine learning approaches for rare and neglected disease drug discovery. He is also the on the SAB of the Pitt Hopkins Research Foundationand Adjunct Professor at 3 US universities. His work is NIH funded (NINDS, NCATS, NIAID, NIGMS). He has authored or co-authored >295 peer reviewed papers, book chapters, and edited 5 books on drug discovery research.

Sessions

12:05 PM - 12:45 PM

Opportunities and Challenges Using AI in unlocking the ADME Tox Obstacles in Drug Development

This session will address how machine and active learning are being applied to solve complex and difficult ADME Tox problems facing the pharma industry.  There will be representation from both in-house and external models as well as pro and con viewpoints on applying AI to the challenges of the ADME/tox field.  Industry innovators and researchers share their efforts in solving these challenges which could be worth hundreds of millions to industry, accelerate drug discovery and be invaluable to patients.
  • What problems are we trying to solve?
  • Do we have the right data to build ADME/Tox models?
  • How do we know when models will be applicable in a drug discovery program?
  • Is Deep Learning the solution to our problems?
  • How can we staff AI in drug discovery?

Moderator

Speakers


Download Latest Agenda